Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12888600 | 0.74 | CXCR3 (0.38) | CXCR3SMN1; SMN2KMT2AMEN1DRD2 | |
| SCHEMBL13763160 | 0.73 | CXCR3 (0.37) | CXCR3SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL3456522 | 0.73 | CXCR3 (0.37) | CXCR3SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL158053 | 0.73 | SMN1; SMN2 (0.67) | CXCR3SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL29652034 | 0.66 | SMN1; SMN2 (0.48) | CXCR3SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL6337655 | 0.66 | SMN1; SMN2 (0.48) | CXCR3SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL4754594 | 0.65 | SMN1; SMN2 (0.38) | CXCR3SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL5707353 | 0.65 | CXCR3 (0.35) | CXCR3SMN1; SMN2KMT2AMEN1DRD2 | |
| SCHEMBL25689888 | 0.65 | KMT2A (0.34) | CXCR3SMN1; SMN2KMT2AMEN1KDM4E | |
| SCHEMBL9120461 | 0.64 | SMN1; SMN2 (0.46) | CXCR3SMN1; SMN2KMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108473526-B | Process for producing oligonucleotide and nucleoside, nucleotide or oligonucleotide | 味之素株式会社 | 2022-08-09 | — | — | CN | claimed |
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | AJINOMOTO CO., INC. (JP) | 2021-02-16 | — | — | US | claimed |
| EP-3398955-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-11-07 | — | — | EP | claimed |
| US-20180282365-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-10-04 | — | — | US | claimed |
| EP-4741411-A2 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2026-05-13 | — | — | EP | disclosed |
| US-12559517-B2 | Oligonucleotide manufacturing method | AJINOMOTO CO., INC. (JP) | 2026-02-24 | — | — | US | disclosed |
| US-12509484-B2 | Method of producing nucleic acid compound, and nucleic acid compound | FUJIFILM CORPORATION (JP) | 2025-12-30 | — | — | US | disclosed |
| CN-116063365-A | Method for preparing oligonucleotide and nucleoside, nucleotide or oligonucleotide | 味之素株式会社 | 2023-05-05 | — | — | CN | disclosed |
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| US-20220259255-A1 | METHOD OF PRODUCING NUCLEIC ACID COMPOUND, AND NUCLEIC ACID COMPOUND | FUJIFILM CORPORATION (JP) | 2022-08-18 | — | — | US | disclosed |
| CN-108473526-B | Process for producing oligonucleotide and nucleoside, nucleotide or oligonucleotide | 味之素株式会社 | 2022-08-09 | — | — | CN | disclosed |
| US-20220235090-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2022-07-28 | — | — | US | disclosed |
| EP-4006045-A1 | NUCLEIC ACID COMPOUND MANUFACTURING METHOD AND NUCLEIC ACID COMPOUND | FUJIFILM Corporation (JP) | 2022-06-01 | — | — | EP | disclosed |
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | AJINOMOTO CO., INC. (JP) | 2021-02-16 | — | — | US | disclosed |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | NISSAN CHEMICAL CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| EP-3398955-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-20180291056-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | AJINOMOTO CO., INC. (JP) | 2018-10-11 | — | — | US | disclosed |
| US-20180282365-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | AJINOMOTO CO., INC. (JP) | 2018-10-04 | — | — | US | disclosed |
| EP-3378869-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Nissan Chemical Corporation (JP) | 2018-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259255-A1 | METHOD OF PRODUCING NUCLEIC ACID COMPOUND, AND NUCLEIC ACID COMPOUND | XRN2, RNASEH1, NSUN2 | CXCR3 874/4885SMN1; SMN2 1386/4885KMT2A 1360/4885 |
| US-20220235090-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | RNGTT, IGF2BP2, DCLRE1B | CXCR3 3270/4885SMN1; SMN2 113/4885KMT2A 2222/4885 |
| US-20180282365-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD, AND NUCLEOSIDE, NUCLEOTIDE, OR OLIGONUCLEOTIDE | NUDT1, RNGTT, POLN | CXCR3 1287/4885SMN1; SMN2 1790/4885KMT2A 3331/4885 |
| US-20180291056-A1 | OLIGONUCLEOTIDE MANUFACTURING METHOD | RNGTT, IGF2BP2, DCLRE1B | CXCR3 3270/4885SMN1; SMN2 113/4885KMT2A 2222/4885 |
| US-10919928-B2 | Oligonucleotide production method, and nucleoside, nucleotide, or oligonucleotide | POLL, POLM, NUDT1 | CXCR3 1154/4885SMN1; SMN2 1357/4885KMT2A 2919/4885 |
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | CXCR3 690/4885SMN1; SMN2 876/4885KMT2A 2395/4885 |
| US-12559517-B2 | Oligonucleotide manufacturing method | POLL, IGF2BP1, POLI | CXCR3 4132/4885SMN1; SMN2 213/4885KMT2A 1117/4885 |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, OSGEP, PHAX | CXCR3 690/4885SMN1; SMN2 876/4885KMT2A 2395/4885 |
| US-12509484-B2 | Method of producing nucleic acid compound, and nucleic acid compound | NSUN2, RNASEH1, XRN2 | CXCR3 998/4885SMN1; SMN2 1379/4885KMT2A 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.